Yu Ge, Yang Wenqi, Ma Yubin, Zhang Ning, Tang Di, Jin Ye, Shi Liang, Wang Mengshu, Liu Dawei, Xue Changying, Sun Bingbing
State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, China.
School of Chemical Engineering, Dalian University of Technology, Dalian, China.
Hum Vaccin Immunother. 2025 Dec;21(1):2545636. doi: 10.1080/21645515.2025.2545636. Epub 2025 Aug 13.
The acellular pertussis (aP) vaccine has increasingly replaced the whole-cell pertussis (wP) vaccine due to its superior safety profile. However, the aP vaccine is less effective at preventing infection and transmission of , highlighting the need for more effective aP vaccines. Current aP vaccines do not elicit the robust cellular immunity necessary to eliminate intracellular bacteria and do not induce sufficient mucosal immunity to prevent bacterial colonization in the upper respiratory tract. Incorporating novel adjuvants represents a promising avenue for the future development of pertussis vaccines. Nevertheless, there remains a significant gap in understanding the application of novel adjuvants. In this article, we summarize the currently approved pertussis vaccines, focusing on the types of antigens and adjuvants used, and discuss the mechanisms of novel adjuvants. This provides valuable insights into the roles of adjuvants in pertussis vaccines, laying a foundation for designing next-generation pertussis vaccines with improved adjuvant systems.
无细胞百日咳（aP）疫苗因其卓越的安全性，已逐渐取代全细胞百日咳（wP）疫苗。然而，aP疫苗在预防百日咳感染和传播方面效果较差，这凸显了开发更有效aP疫苗的必要性。目前的aP疫苗无法引发消除细胞内细菌所需的强大细胞免疫，也不能诱导足够的黏膜免疫以预防上呼吸道细菌定植。添加新型佐剂是百日咳疫苗未来发展的一个有前景的途径。尽管如此，在新型佐剂的应用理解上仍存在重大差距。在本文中，我们总结了目前已获批的百日咳疫苗，重点关注所使用的抗原和佐剂类型，并讨论新型佐剂的作用机制。这为深入了解佐剂在百日咳疫苗中的作用提供了有价值的见解，为设计具有改进佐剂系统的下一代百日咳疫苗奠定了基础。
